RE-BVS – Piemonte Repository

Sfoglia per AUTORE
COLOMBA A
Collezione AOU Città della Salute di Torino

Items : 6

Blood pressure variability as predictor of cancer therapy-related cardiovascular toxicity in patients with Multiple Myeloma. in Hypertension research : official journal of the Japanese Society of Hypertension / Hypertens Res. 2025 Jan 22. doi: 10.1038/s41440-024-02084-w.

2025
ASL Città di Torino
AOU Città della Salute di Torino

Veglio F; Gay F; Bringhen S; Rabbia F; Leone D; Paladino A; Cesareo M; Colomba A; Votta S; Catarinella C; Mingrone G; Astarita A; Airale L; Fanelli E; Picca G; Milan A; Vallelonga F;

Heart failure with preserved ejection fraction: from echocardiographic characteristics to a cardiovascular damage score in a high-risk hypertensive population. in Journal of hypertension / J Hypertens. 2025 Apr 1;43(4):606-614. doi: 10.1097/HJH.0000000000003942. Epub 2024 Dec 10.

2025
AOU Città della Salute di Torino

Ligato J; Mingrone G; Bruno G; Fragapani S; Colomba A; Airale L; Cesareo M; Botta M; Vallelonga F; Leone D; Sanapo M; Veglio F; Milan A;

Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment. in Cancers / Cancers (Basel). 2024 Sep 4;16(17):3081. doi: 10.3390/cancers16173081.

2024
AOU Città della Salute di Torino

Colomba A; Astarita A; Mingrone G; Airale L; Catarinella C; Vallelonga F; Leone D; Cesareo M; Paladino A; Bringhen S; Gay F; Pedrizzetti G; Veglio F; Milan A;

Correction: Colomba et al. Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment. Cancers 2024, 16, 3081. in Cancers / Cancers (Basel). 2024 Nov 21;16(23):3891. doi: 10.3390/cancers16233891.

2024
AOU Città della Salute di Torino

Colomba A; Astarita A; Mingrone G; Airale L; Catarinella C; Vallelonga F; Leone D; Cesareo M; Paladino A; Bringhen S; Gay F; Pedrizzetti G; Veglio F; Milan A;

Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study. in Cancers / Cancers (Basel). 2023 Feb 2;15(3):955. doi: 10.3390/cancers15030955.

2023
AOU Città della Salute di Torino

Astarita A; Mingrone G; Airale L; Cesareo M; Colomba A; Catarinella C; Leone D; Gay F; Bringhen S; Veglio F; Milan A; Vallelonga F;

Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience. in Cancers / Cancers (Basel). 2023 Feb 10;15(4):1149. doi: 10.3390/cancers15041149.

2023
AOU Città della Salute di Torino

Mingrone G; Astarita A; Colomba A; Catarinella C; Cesareo M; Airale L; Paladino A; Leone D; Vallelonga F; Bringhen S; Gay F; Veglio F; Milan A;